

**Thomas Lobl, Ph.D.**

Entrepreneur in Residence (EIR), AMI-USC; Consultant

Tom works with the new project development group at AMI to help identify USC and other technologies which have commercially important potential in biomedical areas. He works with the AMI team to assess the medical/scientific potential of technologies and to help move forward the technology until it is ready to license to a for-profit company or spin out into a start-up company.

Tom has over 45 years of experience in the pharmaceutical and medical device industries and been involved at the bench and management levels in nearly every aspect of pharmaceutical discovery, research and development from idea generation through clinical trials.

Tom has a BS in chemistry from U. North Carolina in Chapel Hill, a PhD from Johns Hopkins U. and post-graduate work at Caltech and Rockefeller U. He began his career at The Upjohn Company (now part of Pfizer) and has worked in both big pharma and a variety of biotech start-up companies in various management positions. In 2002, he joined the Al Mann family of companies at AlleCure/Mannkind as VP of R&D and subsequently as Senior VP of R&D. In January 2004, he helped to start NeuroSystec and was acting CEO for nearly 7 years. NeuroSystec was developing an anti-tinnitus drug and was sold to Otonomy. From October 2011 until October 2015 he worked at the Alfred Mann Foundation as an Emerging Technology Strategist. In November 2015 he began working at the Alfred Mann Institute at University of Southern California as Entrepreneur in Residence and as a consultant. He has over 74 publications and patents and has been a scientific reviewer or editorial board member on a variety of scientific journals. He has been a board member and/or officer of a number of scientific organizations and is currently Past Chair of the American Tinnitus Association Board of Directors and on the KGI Advisory Council. He is/has been on a number of NIH grant review study sections (currently on: Sensory Technologies) and is a consumer reviewer for the (Congressionally Directed Medical Research Program (CDMRP)) administered by the Army.

Tom's scientific and research experience is quite broad and include medicinal and peptide/protein chemistry, drug discovery and development, clinical development, drug and tissue-specific delivery systems in the cancer, inflammatory, infectious, reproductive and endocrinology diseases areas. He joined the AMI in November 2015.